In this regard, IFNAR2 expression in HCC tissues may be a useful predictor of response to such therapy and thus distinguish between responders and nonresponders to IFN-α/5-FU combination therapy. The gene discussed is IFNAR2; the disease is hepatocellular carcinoma.